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S U M M A R Y
The 2008 Recommendations for care of the International AIDS Society reafﬁrmed the importance of both
accurate and sensitive viral load assessment, and by necessity, access to viral load assays. HIV-1 viral load
testing is considered essential when initiating antiretroviral therapy (ART), when monitoring ART
response, and when considering switching ART regimens. The demand for accurate, reproducible, and
cost-effective viral load assays is therefore a global issue. Although the North American and Western
European experience has historically been with HIV-1 group M subtype B virus, this paradigm is
changing rapidly as migrants and refugees from developing countries with non-B subtype infections
often now present for care in the developed world, and travelers to developing countries acquire non-B
subtype infection abroad and present for care at home. Awareness of any clinical or laboratory
differences between the common HIV-1 group M subtype B and the newer HIV-1 strains being seen in
practice is therefore increasingly important. This review of current HIV-1 viral load testing is focused on
the potential value of a standardized genotype assignment for HIV-1 viral subtypes, regular monitoring
of the performance of available commercial HIV viral load assays on emerging non-B HIV subtypes,
circulating recombinant forms (CRFs) and unique recombinant forms (URFs), and a discussion of the
implications for resource-limited settings.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Human immunodeﬁciency virus (HIV-1) plasma RNA viral load
assays have become an essential tool, not only in HIV care, but also
in understanding HIV pathogenesis.1–4 Precision and reproducibil-
ity in the measurement of both plasma HIV-1 RNA levels and the
absolute CD4 T-lymphocyte count are critical as these tests are the
cornerstones of modern HIV care.1,2,5,6 HIV viral load levels are
used to assess an individual’s infectivity,7 to gauge their risks for
disease progression,3 to monitor their response to antiretroviral
therapy (ART),8 and to assess the potential for emergence of viral
resistance.6,9,10 Successful ART therapy is deﬁned in most guide-
lines as suppression of plasma viremia, and is clinically docu-
mented by having two sequential quantitative HIV-1 plasma RNA
measurements that are below the lower quantiﬁcation limit of an
approved viral load assay.6 Clinical trials of novel antiretroviral
drugs or new regimens often use the difference between the pre-
treatment and endpoint HIV-1 plasma RNA level or the rate of
decline of viral load to assess potency.11–14* Corresponding author.
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has historically been with HIV-1 group M subtype B viral infections,
this paradigm is changing rapidly.15–20 In developed countries
travelers may acquire non-B subtype infections abroad and present
for care at home. Migrants and refugees from the developing world
often now present for care in the developed world with strains
reﬂective of the wide diversity of the global HIV pandemic.
Secondary spread of non-B subtypes within the developed world
is also recognized. Awareness of any clinical or laboratory differences
between the common HIV-1 group M subtype B and the newer HIV-1
strains being seen in practice is increasingly important.
The 2008 Recommendations for care of the International AIDS
Society reafﬁrmed the importance of both accurate and sensitive
viral load assessment, and by necessity, access to viral load
assays.21 HIV-1 viral load testing is considered essential when
initiating ART, when monitoring ART response, and when
considering switching ART regimens. The demand for accurate,
reproducible, and cost-effective viral load assays is therefore a
global issue.22–24 The potential value of a standardized genotype
assignment for HIV-1 viral subtypes, regular monitoring of the
performance of available commercial HIV viral load assays on
emerging non-B HIV subtypes, circulating recombinant forms
(CRFs) and unique recombinant forms (URFs), and the implications
for resource-limited settings are discussed herein.ses. Published by Elsevier Ltd. All rights reserved.
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HIV has two main viral types, designated as HIV-1 and HIV-2.
While HIV-2 infection is most prevalent in West Africa, there are
small numbers of patients with HIV-2 infection distributed
worldwide. The HIV-2 virus is typically much less pathogenic
and also has a lower plasma viral load. The challenge for viral load
monitoring in HIV-2 patients is two-fold. First, the currently
available HIV-1 commercial kits are not targeted to HIV-2
sequences. Second, HIV-2 virus can be divided into at least eight
subtypes, with subtypes A and B being the most prevalent.25,26 This
genetic heterogeneity within HIV-2 makes divergent HIV-2 strains
(non A and B) difﬁcult to quantify even with ‘in-house’ PCR/
primers aimed at HIV-2 subtypes A and B.27,28 A recent quality
control comparison of HIV-2 (subtype A) viral load quantiﬁcation
between nine laboratories again highlighted the variation in HIV-2
viral load determination and the lack of a standardized assay.29
Several groups are classiﬁed within HIV-1 including M (major),
N (new), O (outlier), and recently P virus.30 HIV-1 group M is the
most common group seen in clinical practice. Using established
criteria, HIV group M has been divided into subtypes A–D, F–H, and
J–K and several of these subtypes have been further delineated
(e.g., subtypes A and F have several sub-subtypes A1–4 and F1–2)
as well as CRFs (48 different CRFs have been described to date) (Los
Alamos National Laboratory, http://www.hiv.lanl.gov).31–33 A CRF
must be fully sequenced and discovered in three or more
epidemiologically unlinked individuals to be designated as such,
otherwise rare viral types are called unique recombinant forms
(URFs) if they do not meet these criteria.33
The extensive genetic variability of the HIV-1 virus is the
product of several mechanisms: host factor immune selection
pressures,34 a lack of proof-reading activity of the reverse
transcriptase gene (which leads to a mutation rate of approxi-
mately 3.4  105 mutations per base pair per replication
cycle),33,35 a rapid turnover rate in vivo,35 and recombination
between two separate replicating strains of virus within a single
cell in a given patient.33,36,37 These virological mechanisms lead to
extensive variation between one subtype and another. Not only
does this lead to substantial genome variance across subtypes and
populations, but also to millions of variants of a given HIV virus
within a single affected individual. The historic parameters for
genetic variability are 15–20% within a subtype, whereas variation
between separate subtypes can be >30% based on the envelope
gene region.33,38 These traditional subtype classiﬁcations may
prove to be less useful as we begin to appreciate the extent of the
dynamic genetic evolution of HIV-1.31,33,38–40
The emergence of CRFs that are a product of recombination
between viral subtypes in a dually-infected individual, further
complicates HIV subtyping. CRFs may be unique to the individual
in that the recombination occurred or was transmitted as an
established crossover strain to newly infected individuals.
Although the incidence of new infections with recombinant
strains is on the rise, their clinical implications have not been
fully elucidated.31,33,38–41
The global distribution of prevalent HIV-1 subtypes for the
periods 2000–03 and 2004–07 continues to be markedly
different by geographical region.31,38 Although the broad
distribution of HIV-1 subtypes worldwide has been stable over
this period of time, there has been an overall increase in
recombinants, most notably CRFs. In 2004–07, nearly one half of
all global infections were caused by subtype C (48%), followed by
subtypes A (12%) and B (11%), CRF02_AG (8%), CRF01_AE (5%),
subtype G (5%), and subtype D (2%).31 Overall, subtypes F, H, J
and K cause less than 1% of infections worldwide. Other
recombinant forms (CRFs and URFs) together cause 4% of global
infections, and combined with the burden of CRF02_AG andCRF01_AE infections, 20% of known HIV infections worldwide are
currently caused by all recombinants.31 The HIV-1 subtype A and
recombinant form A/G is prevalent in West and Central Africa.
Subtype E and crossover A/E is most prevalent in Southeast
Asia.31,39,40,42 Subtype C is generally found in South and East
Africa, as well as India and Nepal. Subtype D is mostly limited to
East and Central Africa. Comparison of viral load assays in
African regions with multiple HIV-1 subtypes has been promis-
ing.43 Subtype F is seen mostly in Central Africa and Eastern
Europe, while subtype G and crossover form A/G is observed in
both Africa and Central Europe. Subtype H is mostly conﬁned to
Central Africa, while subtype J is seen only in Central America,
and K in Cameroon and the Democratic Republic of Congo.31,43
3. Impact of migration and travel on the global spread of
diverse HIV subtypes
HIV-1 group M subtype B remains the predominant viral
infection throughout North America and most developed coun-
tries, yet accounts for only a small proportion (11%) of total global
infections.31,38,44 Globally, the majority of new infections occur
with subtype C, which has the highest global prevalence (48%) in
currently infected individuals.31 The immigration policy of the USA
historically included HIV/AIDS as grounds for inadmissibility to the
country; this was the case for more than 20 years, under legislation
passed in 1987 and subsequently in 1999.45–47 Canada, as well as
many European countries, did not declare HIV infection as a
speciﬁc criterion for inadmissibility for immigrants. As such, the
impact of emerging viral diversity is more apparent in countries
with open immigration policies due to a higher proportion of non-
B subtypes entering care.48–50 Because US public policy only
changed in 2009 with regard to admission of HIV-infected persons,
the impact on viral diversity may not be as apparent in the USA as
elsewhere for many years to come.51 While migration explains
much of the diversity being seen with HIV subtypes, travel with
HIV acquisition abroad and also within-country transmission of
the non-B subtypes is also seen,50 demonstrating that even
countries with the most stringent immigration requirements will
not be immune to increasing viral diversity.
Our local experience with a cohort of Canadian HIV patients in
Southern Alberta exempliﬁes the impact of policy and travel and
migration patterns in driving an increasing proportion of non-B
and crossover recombinant HIV-1 infections.16,50 The Southern
Alberta HIV Clinic (SAC) program in Calgary provides care to all
patients diagnosed with HIV in the southern part of the province.
Figure 1 shows the increasing percentage of patients in care with
non-B subtype infections over the last decade. As viral diversity
expands, the traditional viral subtype classiﬁcations may need to
be combined with the standardized resistance genotype assign-
ment database.32,52 Much more research also needs to be done to
determine the optimal laboratory support and the differences in
disease course, response to treatment, and resistance patterns that
emerge under selective drug pressure for all non-B subtype
infections.53,54
The diversity of HIV viral subtypes within the Canadian
population raises an important concern about the long-term
ability of commercial molecular-based HIV-1 viral load tests,
developed to primarily detect and quantify HIV-1 group M subtype
B HIV-1 sequences, to remain accurate and valid when used to test
and manage patients with non-B subtypes and CRF infections. Due
to the importance of viral load testing in support of clinical care,
the differences of the available platforms and their methodologies
need to be understood. The challenges and limitations of each
platform can then be better addressed as HIV diversity expands
into laboratories mainly familiar with testing HIV-1 group M
subtype B viruses.
Figure 1. Active patients with HIV-1 group M subtype and circulating recombinant form (CRF) infections attending the Southern Alberta Clinic Program (1990–2010).
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Currently there are four commercially available HIV-1 viral load
quantiﬁcation assays that have been approved for patient testing by
the US Food and Drug Administration (FDA); these include: (1)
RealTime HIV-1: m2000rt instrument (m2000rt; Abbott Molecular
Diagnostics), (2) COBAS AmpliPrep TaqMan HIV-1 48 (CAP-CTM;
Roche Molecular Diagnostics), (3) EasyQ HIV-1 v1.2 assay (EQ;
bioMe´rieux), and (4) VERSANT 3.0 HIV-1: VERSANT 440 instrument
(bDNA; Siemens). All of these assays use real-time PCR (qrtPCR) to
quantify HIV RNA in plasma samples, except for VERSANT which is aTable 1
Speciﬁcations of FDA approved commercial HIV viral load assaysa
Item Abbott RealTime HIV-1
(m2000rt)
COBAS TaqMan 48
HIV-1 (Roche)
HIV target region Highly conserved region
within pol (integrase)
Highly conserved r
the gag gene
Internal control Yes (non-competitive
pumpkin gene)
Yes 
Ampliﬁcation Real-time PCR target
ampliﬁcation
Real-time PCR targ
ampliﬁcation (TaqM
Detection Fluorescence Fluorescence 
(Partially double-stranded
HIV-1 labeled ﬂuorescent
reporter probe – 50 end and
a short oligo ﬂuorescent
quencher probe – 30 end
complimentary to 50-HIV probe)
(TaqMan dual labe
ﬂuorescent probes 
and HIV-QS-speciﬁ
with different repo
quencher dyes)
Quantitation May be reported in multiple
formats: copies/ml, log10
copies/ml, IU/ml or log10 IU/ml;
conversion factor to IU/ml is
1 IU = 0.56 copies and 1
copy = 1.74 IU
Reported in copies/
factor to IU/ml is 1
copies and 1 copy =
Linear dynamic range
(lower and upper limits)
40 copies/ml from 600 ml 40 copies/ml from 
10 million copies/ml 10 million copies/m
Speciﬁcity (%) (95% CI) 100 (95% CI 98.05–100) 100 (95% CI 99.3–1
HIV subtypes Group M – subtypes A–D,
CRF01_AE, CRF02_AG,
subtypes F–H, group N and O
Group M – subtype
CRF01_AE
FDA, US Food and Drug Administration; NASBA, nucleic acid signal branch ampliﬁcatio
a Speciﬁcations taken from the manufacturer’s instrument(s) and kit product informbranched DNA endpoint detection assay. A new qrtPCR assay has
been developed by Siemens to replace bDNA, but the pkPCR assay has
not yet been approved by the FDA and will not be further discussed.55
The m2000rt assay targets a conserved region of the pol-integrase
genes and ampliﬁes HIV-1 RNA using a partially double-stranded
qrtPCR method (Table 1). A partial sequence of the pumpkin
polymerase gene acts as the internal control. According to the
manufacturer, this assay reliably detects HIV-1 group M, A–D and F–
H viruses, several CRFs, including CRF01-AE and CRF02-AG as well as
group N, and O. Puriﬁed RNA is extracted from a minimum of 0.6 ml
plasma sample using the m2000sp automated extractor, and qrtPCRNucliSENS EasyQ
HIV-1 v1.2 (bioMe´rieux)
VERSANT 440 HIV-1
RNA v3.0 (Siemens)
egion of Highly conserved region
within gag
Several regions of pol
No No
et
an)
Real-time NASBA bDNA signal ampliﬁcation
Fluorescence – molecular
beacons
Chemiluminescence
led
(HIV-1
c oligo probes)
rter and
(Multiple copies of alkaline
phosphatase labeled probe
incubated with CL substrate –
light emission equivalent to
quantity of HIV RNA in sample)
ml; conversion
 IU = 0.6
 1.7 IU
Reported in copies/ml;
1:1 conversion to IU
Reported in copies/ml
850 ml 25 copies/ml to 10 million
copies/ml
50 copies/ml to
l 500 000 copies/ml
00) 100 100 (95% CI 98–100)
s A–D, F–H; Group M – subtypes
A–D, F–H, J
Group M – subtypes A–D, F–H
n; CL, chemiluminescent; CI, conﬁdence interval.
ation.
Table 2
Comparison of sample requirements for commercial HIV viral load assaysa
Item Abbott RealTime
HIV-1 (m2000rt)
COBAS TaqManTM
48 HIV-1 (Roche)
NucliSENS EasyQ
HIV-1 v1.2 (bioMe´rieux)
VERSANT 440 HIV-1
RNA v3.0 (Siemens)
Acceptable specimens Human plasma in ACD-A
or EDTA, DBS
Human plasma in
EDTA, DBS
Human plasma in EDTA,
DBS, tissues
Human plasma in
CD-A, K2PPT or EDTA
Specimen volume 1.0 ml optimal but uses 0.6 ml;
rest is stored
1.0 ml optimal but
uses 0.85 ml; rest is
discarded
0.5–1.0 ml 1.0 ml
Storage prior
to testing
Whole blood: RT 6 h/2–8 8C 24 h Whole blood: RT 6 h Whole blood: RT 4 h Whole blood: RT 4 h
Plasma: RT 24 h/2–8 8C 5
days/80 8C indeﬁnite
Centrifugation: 20 min Plasma: 48 h 2–8 8C/80 8C
indeﬁnite
Plasma: 48 h 2–8 8C/80 8C
indeﬁnite
Freeze/thaw: once Plasma: RT 24 h/2–8 8C 5
days/80 8C indeﬁnite
Freeze/thaw: 3 Freeze/thaw: 3
Freeze/thaw: 5
Specimen prep
prior to lysis
Clarify by centrifugation at
2000 g  5 min, uncap tubes;
place into rack with labels
facing out
Attach barcoded clips to rack,
add K-tube, vortex specimen
3–5 s; pipette into specimen
container, place into rack
Instrument pipettes lysis buffer;
pipette specimen into tubes,
mix and add silica/IC mix
Centrifuge at 23 500 g  1 h
at 2–8 8C; remove supernatant;
immediately freeze at 86 8C
for at least 30 min
Lysis Sodium guanidine thiocyanate Incubated at elevated
temperature with protease
and chaotropic lysis/binding
buffer (RNAse)
Sodium guanidine thiocyanate/
high salt concentration
Proteinase K
RNA capture/
elution
Magnetic particle/water Generic silica based capture
technique/eluted at elevated
temperature with an aqueous
solution
Magnetic silica/water Polystyrene microwells coated
with synthetic oligonucleotides/
RNA coated in well
ACD-A, acid citrate dextrose solution A; EDTA, ethylenediaminetetraacetic acid; DBS, dried blood spots; K2PPT, K2 plasma preparation tube; RT, room temperature; IC,
internal control.
a Speciﬁcations taken from the manufacturer’s instrument(s) and kit product information.
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m2000rt instrument. The assay dynamic range is 1.60 to 7.0 log10
copies/ml for this amount of plasma.
The CAP-CTM assay targets a conserved region of the gag p41
gene and uses TaqMan differential ﬂuorescence tagged primers to
amplify HIV-1 RNA. Additional ﬂuorescence primers and probes
detect quantiﬁcation standards, and a partial sequence of the long
terminal repeat (LTR) region acts as the internal control (Table 1).
According to the manufacturer, this assay reliably detects HIV-1
group M, A–D and F–H viruses and several CRFs including CRF01-AE.
Puriﬁed RNA is extracted from a 1.0-ml plasma sample using the
COBAS AmpliPrep, and qrtPCR ampliﬁcation and detection is done
using the fully automated COBAS TaqMan 48 instrument. The assay
dynamic range is 1.6 to 7.0 log10 copies/ml for this amount of plasma.
The EQ assay uses a molecular beacon targeted to the gag p24
gene to perform qrtPCR isothermal nucleic acid ampliﬁcation of the
sample RNA compared to internal quantiﬁcation calibrators added
to the reaction mixture (Table 1). According to the manufacturer, this
assay reliably detects HIV-1 group M, A–D and F–H, J viruses. Puriﬁed
RNA is obtained from a 1.0-ml plasma sample using the EasyMAG
automated extractor, and qrtPCR ampliﬁcation and detection is done
using the automated EasyQ instrument. The assay dynamic range is
1.60 to 6.7 log10 copies/ml for this amount of plasma.
The bDNA assay targets a highly conserved region of the pol
gene, and several primers and probes are used to perform signal
ampliﬁcation of branched DNA across this region (Table 1).
According to the manufacturer, this assay reliably detects HIV-1
group M, A–D and F–H viruses. Puriﬁed RNA is extracted from a
1.0-ml plasma sample, and qPCR ampliﬁcation and detection of the
bDNA assay is performed using the VERSANT 440 v.3.0 instrument.
This assay does not use an internal control. The assay dynamic
range is 1.7 to 5.7 log10 copies/ml for this amount of plasma.
All of the commercially available HIV viral load assays have
variable specimen collection and preparation requirements, and
complex requirements for the automation and performance of the
analysis and reporting procedures. For these reasons and the need
for highly trained technologists with considerable molecular
experience to reliably perform HIV-1 viral load assays, this testis centralized in both developed and resource-limited countries to
large reference laboratories with adequate specimen transporta-
tion infrastructure systems.
HIV-1 viral load sample collection, processing, and transporta-
tion requirements are summarized in Table 2. Blood must be
collected into tubes containing either EDTA or acid citrate dextrose
(ACD) as an anticoagulant for all of the qrtPCR assays, depending on
the manufacturer’s requirements. Heparin (PPT) tubes may also be
used if performing bDNA. However, regardless of the assay, EDTA
tubes are preferred because there is less degradation of HIV RNA
and thus higher viral load results (at both 400 and 50 copies/ml
levels of quantiﬁcation) compared to using PPT tubes.56 Whole
blood specimens must be promptly transported at room tempera-
ture (i.e., within 4–6 h of collection) from phlebotomy sites that do
not have the ability to separate plasma, except for the Abbott
m2000rt assay which allows blood to be refrigerated for up to 24 h
prior to plasma separation. A major advantage of the qrtPCR assays
is that plasma may be stored and transported at room temperature
prior to testing. When plasma samples were stored at tempera-
tures up to 30 8C for 1 week, it did not affect HIV-1 RNA
quantiﬁcation,57 but storage at higher temperatures (i.e., 37 8C)
that would be very germane in some resource-limited countries,
resulted in signiﬁcantly reduced median HIV-1 RNA levels.
Refrigeration of plasma samples prior to testing, which is required
by the bDNA and other older qPCR assays, presents a major
problem for resource-limited settings. Individual plasma samples
may be freeze-thawed multiple times during testing, except for the
Abbott m2000rt assay where plasma may only be thawed once.
Considerable research has also gone into developing and
validating dried blood spots (DBS) as an alternative collection
method for HIV-1 viral load testing, which obviates the need to
transport, refrigerate or freeze, and process blood/plasma sam-
ples.58–60 A study using NucliSENS and Amplicor assays in Mexico
found that HIV-1 RNA in dried blood samples from different climates
demonstrated statistically signiﬁcant correlation with plasma
levels,61 as did a second study of NucliSENS in Senegal.62 Another
recent study undertaken in Cameroon showed a statistically
signiﬁcant correlation between plasma and dried blood HIV-1
Table 3
Ease of use and efﬁciency comparison of HIV viral load platformsa
Item Abbott Molecular Diagnostics Roche Diagnostics bioMe´rieux Siemens Medical Solutions
Instrumentation m2000sp + computer
and m2000rt + computer
UPS included
COBAS Ampliprep + TaqMan
48 + computer UPS included
EasyMAG (extraction)b + computer
and EasyQ instrument + computer
UPS included
VERSANT 440 instrument
with integrated computer
UPS included
Ease of use Fully automated walk away;
very easy to load with lots of
prompts
Straightforward to use;
software needs to be in
right screen to prompt load;
cartridges fussy to load –
won’t accept
Easy to use; automated extraction
and ampliﬁcation/detection 2 steps;
manual pipetting of master mix
Labor intensive; instrument
malfunction (picked up LP
tube during run) and lost
85 test results
Barcode reader Yes No Yes Yes
Pipetting steps Internal control to extraction
buffer prior to reagent loading
Pipetting of specimen to
Roche specimen tubes
Additional pipetting steps during
extraction and ampliﬁcation set-up
Lots of additional pipetting
steps
Millenium (Cerner)
interface
Yes – bidirectional Yes – bidirectional Yes – results reporting Yes – results reporting
Instrument errors None 2 crashes affecting 9
specimens and 3 no
specimen errors
EasyMAG computer freezes at load;
3% rate of invalid results
Major error whereby LP tube
breaks – not picked up: no
results for 85 specimens
a As documented by a dedicated senior molecular technologist who was trained and certiﬁed on each platform, and who sequentially ran a large number of assays on each
platform as part of our recent large multi-assay comparison study().
b EasyMAG extractor must be routinely serviced/cleaned or rate increased due to specimen contamination as previously described Church et al.64
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newer qrtPCR assays indicate that testing may be done on DBS
samples, limited data are available to validate that claim from a large
number of centers.
Newer HIV-1 viral load assay platforms have either fully or
partially automated the major procedural steps, including sample
extraction, ampliﬁcation, and detection. Table 3 summarizes the
documented ease of use of each of the HIV-1 viral load assay
platforms by a senior molecular technologist, who was trained and
certiﬁed to perform testing on each assay platform during our recent
large multi-assay HIV-1 viral load study of 369 patients attending
two Canadian HIV clinics with diverse subtype infections.64
The Abbott m2000rt assay is currently the most fully automated
and easy to use instrumentation platform available; minimum
hands-on time is required for specimen preparation prior to
loading on the instrument (i.e., the internal control has to be
pipetted into the extraction buffer prior to reagent loading), the
instrument is very easy to load and has lots of user prompts, and no
instrument errors occurred so that a result was obtained for all of
the cases tested during our study.64
The CAP-CTM assay is also easy to use, but the samples have to be
pipetted into Roche’s specimen tubes prior to loading onto the
instrument. Although the CAP-CTM platform is fully automated once
the specimen cartridges are loaded, the instrument tracks did not
consistently accept the cartridges at initial load, and there is
currently no barcode reader. Two instrument crashes affecting nine
specimens and three specimen errors occurred with the CAP-CTM
platform so that a result was only obtained in 97% of the cases tested
during our study.64
The EQ assay is also easy to perform, although the specimen
extraction and ampliﬁcation/detection procedures are performed
on two separate instruments and require many manual pipettingTable 4
Efﬁciency of real-time HIV viral load assaysa
Item Abbott RealTime HIV-1 m2000rt
Prep time before loading for extraction 30 min 
Number of tests/run 96 
Extraction time 2.5 h/48 tests 
Detection time 3 h 
Workﬂow and time to results 6 h 
Total labor costs per run (CDN)b $38.80 ($0.40/test) 
a Efﬁciency of each assay documented as part of our recent large multi-assay compa
b Costs are calculated in Canadian dollars (CDN) based on the current rate (2008) for a m
and services tax (GST).steps. The EasyMAG instrument required cleaning and decontami-
nation at least every 5 days to avoid invalid results due to bacterial
contamination of the internal calibrator.65 Due to instrument
errors, invalid results, and reagent problems, a result was only
obtained 92% of the time using the EQ platform to test a large
number of samples during our study.64
The bDNA assay run on the VERSANT 440 instrument is the
most labor intensive system and requires a lot of additional
pipetting steps for specimens and reagent preparation time prior
to instrument loading. A major instrument error also occurred
during one run of 85 patient specimens whereby the LP tube broke
and was not picked up, so that no result was obtained for only 75%
of the cases tested during our study .64
The overall workﬂow efﬁciency of each of the three qrtPCR
assays was also documented as part of our recent large multi-assay
comparison study. Table 4 shows a breakdown of the technical
workﬂow analysis and time required for each major step required
to perform the m2000rt, CAP-CTM, and EQ assays, along with the
total labor costs per run for each of these systems. Total labor costs
for performing the bDNA assay are much higher than any of the
qrtPCR assays due to the less automated nature of this platform
(data not shown). The m2000rt assay has the lowest associated
labor cost per test because this fully automated system is able to
simultaneously run the highest number of samples with the least
specimen preparation time. The CAP-CTM has a longer specimen
preparation time than the m2000rt assay, but overall the same
time (6 h) is required to complete a run of 48 tests compared to 96
tests per run for the m2000rt system. The CAP-CTM assay therefore
has a higher labor cost per test than the m2000rt assay. Although
the EQ assay takes less time (4 h) to complete a run of 48 tests
compared to either of the other two assays, it has a comparable
labor cost per test to the CAP-CTM assay because the system is not COBAS TaqManTM HIV-1 NucliSENS EasyQ HIV-1 v2.0
2 h 1 h
48 48
2 h/24 tests 40 min/24 tests
3.75 h 1 h
6 h 4 h
$51.43 ($1.07/test) $41.50 ($0.86/test)
rison study (Church et al.64).
edical laboratory technologist salary and the costs of materials including the goods
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during the extraction and ampliﬁcation/detection procedures.
5. HIV viral load testing: implications of HIV diversity
Until the recent development of the quantitative PCR (qrtPCR)
commercial assays there has been limited standardization of the
performance and reporting of the results from different commercial
manufacturer’s HIV-1 viral load tests. Diagnostic limitations of the
earlier assays included target detection of primarily HIV group M
subtype B viruses, variation between different molecular methods
for performing quantiﬁcation (i.e., nucleic acid signal branch
ampliﬁcation (NASBA), PCR endpoint detection, and bDNA signal
ampliﬁcation), variable assay dynamic ranges, and non-standardi-
zation of the HIV viral load level against an international
quantiﬁcation standard, which all resulted in the reporting of results
in a non-standardized format (i.e., copies/ml vs. log10 IU/ml).
66,67
Results ofearlierversionsofHIV-1 viral loadassaysfor agivenpatient
may thereforenotbereadily comparablebetweendifferentmethods.
Indeed clinically signiﬁcant (i.e., 0.5 to 1.0 log) differences in results
have at times been reported between individual assay platforms
across the dynamic ranges of these assays for the same samples.68–75
Although an early small-scale comparison of viral load assays in
African regions with multiple HIV-1 subtypes did not raise
concerns,63 collaboration between our regional clinical microbiol-
ogy laboratory and the major HIV clinic in Southern Alberta (i.e.,
SAC) recently identiﬁed several cases with non-subtype B infection
where HIV-1 viral load levels were false-negative or grossly under-
quantiﬁed using the EasyQ v1.2 assay (bioMe´rieux, Laval, QC,
Canada).74 Table 5 outlines the HIV subtype, country of origin, and
comparative HIV viral load results obtained using EQ, bDNA, and in
some cases HIV-1 Monitor v1.5. Eleven of the 12 patients had non-
subtype B infections. All of these patients also had CD4 counts
diagnostic of AIDS and likely had longstanding HIV infections,
which have been associated with increasing viral diversity due to
the emergence of many quasispecies within a given subtype.76 In
one case with a subtype G infection, repeatedly negative HIV-1
viral load results by the EQ system resulted in lack of recognition of
inadequate viral suppression, which contributed to an avoidable
transmission of HIV-1 from a new mother to her infant.77
Other qrtPCR HIV-1 viral load assays (m2000rt and CAP-CTM)
have now been developed and are increasingly replacing these older
assay methods in clinical laboratories. Evaluations of these qrtPCR
assays reported to date have shown an improved quantiﬁcation both
across a broader dynamic range (0 up to >7.0 log10 IU/ml) and for a
wider variety of HIV groups and subtypes.78–80 HIV viral load assays
that use the qrtPCR methods have incorporated primers and probesTable 5
Discordant HIV-1 viral load results using EasyQ v1.0–1.2 assays in the Calgary Region 
Patient HIV subtype Country of origin NASBAa (log1
A H/J Congo <LDL 
B G Nigeria <LDL 
C B Canada <LDL 
D A1 Sudan <LDL 
E A/G Ivory Coast 2.3 
F G Nigeria <LDL 
G G Oman <LDL 
H G Sudan <LDL 
I C Ethiopia 2.94 
J Unknown Thailand 1.93 
K C Zimbabwe 2.49 
L A/G Nigeria 1.78 
NASBA, nucleic acid signal branch ampliﬁcation; LDL, lower detection limit; ND, not d
a EasyQ v1.1.
b VERSANT v3.0.
c HIV-1 Monitor v1.5.to detect and quantify group M non-B subtypes, as well as group N
and O viruses,78,80–84 due to previously recognized assay problems
because of the sequence diversity of such strains.85–87 Only the
Abbott RealTime HIV assay has successfully detected an HIV-1 group
P infection.30 Failure of target ampliﬁcation detection of HIV-1
subtype G (based on two commercial HIV RNA ampliﬁcation
techniques) was seen with earlier versions of the Amplicor and
Quantiplex assays.75 The HIV-1 group P index case was not detected
using a gag gene target for ampliﬁcation.30 The increasing
prevalence of recombinant/crossover forms also poses a testing
challenge. Recombinant form CRF02_AG has been under-detected
by commercial assays – both earlier generation assays and currently
available viral load assays.68,82 It is hard to determine how well
commercial assays perform with rarer recombinants due to the
heterogeneous nature of the target sequences and their prevalence
in isolated geographic regions.20,88–92 So far there has been limited
clinical evaluation of currently available HIV-1 viral load assays in
patients with diverse HIV subtype infections,81–85,93 but there have
been several recent reports on the clinical impact of an under-
quantiﬁcation of group M non-subtype B infections.84–87,94,95
Due to concerns about the performance of our current HIV-1 viral
load assay, we undertook a large multi-assay comparison of the three
FDA approved qrtPCR HIV viral load manufacturer platforms and
included bDNA for comparison of an earlier assay version still used
by many laboratories, in order to determine the optimal testing
platform for our increasingly diverse patient population.64Our study
showed that performance signiﬁcantly varied between HIV viral load
platforms according to subtype, and highlighted that HIV viral
diversity in the population being tested must be assessed and
considered in the selection of a viral load platform. A total of 371
samples were tested from 369 patients attending two Canadian HIV
clinics of whom 291 (81%) had a Virco genotype result: B (195, 53%)
and non-B (96, 26%) subtypes A–D and F–K, as well as CRFs (i.e.,
CRF01_AE and CRF02_AG). Most (58/78, 74%) patients of unknown
subtype were recent African emigrants who likely had non-subtype
B infections.64 None of the assays detected or accurately quantiﬁed
all of the samples within the accepted clinical range required.
Although m2000rt (eight samples) and CAP-CTM (nine samples) had
low rates of false-negatives, the non-detected samples were
different for each assay, likely reﬂecting primer and probe
mismatches in the pol-int and gag target regions, respectively.96
However, both of these qrtPCR assays had a much lower rate of false-
negatives and under-quantiﬁcation of samples by 1.0 log10 copies/
ml compared to EQ.64 Although bDNA had a small number of false-
negatives, this qPCR assay had a higher rate of under-quantiﬁcation
compared to the three qrtPCR assays. Some interesting discrepancies
were found in the ability of these assays to detect and quantify HIV(2007–2009)
0) bDNA
b (log10) PCR
c (log10) CD4 (%) (normal
range >30%)
3.61 4.09 17
4.99 ND 10
3.65 ND 16
2.72 ND 24
4.25 ND 13
3.55 ND 12
3.86 ND 14
3.97 ND 9
4.83 >5.0 9
3.84 ND 15
3.76 ND 20
4.25 ND 7
etected.
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by either m2000rt or CAP-CTM occurred for patients with subtype B
infections (10/17, 59%), while most of the under-quantiﬁcation with
either of these assays occurred for non-B subtypes (8/12, 67%).64
However, the EQ and bDNA assays mainly gave false-negatives (18/
25, 72%) or under-quantiﬁed results by 1.0 log10 copies/ml (32/41,
78%) for patients with non-B subtype infections, although some
subtype B strains were also not detected by EQ or were under-
quantiﬁed by both assays.64 Although a wide range of non-B
subtypes were not detected or under-quantiﬁed by the EQ and bDNA,
EQ had difﬁculty with subtype C, A1, AG, G and CRF02_AG templates,
while bDNA has difﬁculty with subtype C templates.64 This ﬁnding
conﬁrms the previously reported difﬁculties these platforms have
with particular HIV-1 viral templates.48,69,85,97 Although the EQ
assay also uses qrtPCR detection, the lower correlation with either
m2000rt or CAP-CTM results may be due to a combination of
instability in the method (i.e., molecular beacon approach) and
mismatches between the probe and primers and the gag target
region, particularly when presented with a diversity of HIV-1 viral
strains.96 Our results conﬁrm the concern that commercial qrtPCR
assays utilizing molecular beacon (EQ) and to some extent TaqMan
qrtPCR methods may not be as reliable as other molecular strategies
when measuring highly polymorphic targets.69,85,93
Previous studies of the newer qrtPCR assays have shown similar
but more limited results when testing patients with diverse types of
HIV-1 infection, but none have studied the performance of all of the
currently available commercial assays. Most recently, Holguin et al.82
compared the performance of VERSANT v3.0 (bDNA), CAP-CTM, and
EQ in testing 83 plasma specimens from patients infected with HIV-1
non-B subtypes and recombinants, as deﬁned by phylogenetic
analysis of the pol gene. Only 32 (58.2%) samples from naı¨ve patients
were quantiﬁed by the three methods: EQ gave the highest HIV RNA
values (mean 4.87 log10 copies/ml) and bDNA the lowest (mean 4.16
log10 copies/ml). Viremia differences of 1.0 log10 copies/ml were
found in eight (14.5%) of 55 specimens, occurring in 10.9%, 7.3%, and
5.4%, respectively, of the specimens in comparisons of bDNA vs. EQ,
bDNA vs. CAP-CTM, and CAP-CTM vs. EQ.82 Differences greater than
0.5 logs, considered signiﬁcant for clinicians, occurred in 45.4%,
27.3%, and 29% when the same assays were compared. Some HIV-1
strains, including subtype G and CFR02_AG, showed more distinct
discrepancies in comparing the results from the different assay
platforms.82 In another recent study, Gueudin et al.81 compared the
performance of the Abbott m2000rt and Roche CAP-CTM assay
platforms for their capacity to quantify various HIV-1 subtypes. The
systems were tested on culture supernatants belonging to HIV-1
group M, group O, and HIV-2, as well as on samples from patients
infected with HIV-1 group M and other strains. The m2000rt system
quantiﬁed all 29 HIV-1 group M supernatants and 7/8 group O
viruses, while the CAP-CTM system did not detect one CRF02strain.81
Both of these assays did not detect any of the HIV-2 strains. Four
samples were under-quantiﬁed by CAP-CTM by >1 log10 copies/ml.
Another recent study by Rouet et al.98 compared a generic HIV viral
load assay with EQ and the Amplicor HIV-1 Monitor v1.5 assay for
quantiﬁcation of non-B subtypes in a resource-limited setting (i.e.,
the Kesho Bora preparatory study). Although the generic assay
detected all of the non-B subtypes, nine samples were not detected
by either the EQ (n = 2) or Monitor (n = 7) assays.
6. HIV-1 viral load measurement: alternative approaches
The disproportionate disease burden of HIV-1 infection in
resource-limited areas and the increasing deployment of ART in
these countries make access to viral suppression monitoring assays
an urgent requirement. However, substantial infrastructure
barriers outlined above remain to implementing a commercial
HIV-1 viral load platform in remote, rural, or resource-limitedhealthcare locations. Alternative diagnostic assays and approaches
are needed that allow universal access to accurate HIV-1 viral load
therapeutic monitoring worldwide.
Global laboratory centers of excellence for HIV-1 viral load
testing could be established in resource-limited areas where one of
the newer qrtPCR assays (m2000rt or CAP-CTM) could be used to
perform centralized testing within a large HIV care network on
dried blood or plasma spot samples. These centralized laboratories
could also monitor HIV subtype diversity within a given region and
document false-negatives and under-quantiﬁcation issues so that
current assays could be modiﬁed to address these problems. For
these centers to be effective, efﬁcient specimen transportation
networks would need to be developed that allow transfer of
samples from remote, rural areas into the centralized facility
within 24 h after collection. A centralized database within each
central laboratory and routine transfer of data to a global database
would create a large repository of samples for surveillance of
evolving HIV diversity, genotypes, and viruses.
In-house or home-made RT-PCRs have also been developed and
used within central laboratory facilities, particularly in resource-
limited countries where commercial assays are too expensive and
the kits may not detect all HIV groups and subtypes or CRFs.23,24,99–
101 Although this approach would not be feasible in de-centralized
laboratories in remote or resource-limited areas, the required
expertise to design complex primers/probes for these assays, as
well as the necessary laboratory infrastructure could be housed in
a centralized regional laboratory. All in-house developed assays
could also be standardized against a developed set of global
controls based on viral subtype.
Other available solutions for viral load assessment in developing
countries include the Ultrasensitive p24 Antigen Assay (PerkinEl-
mer) and the Cavidi ExaVir Load Reverse Transcriptase Assay.102–104
The use of these assays in resource-limited areas has been described
in detail elsewhere.100,101 In brief, although cost-effective and more
feasible in certain geographical areas, there are important limita-
tions with both of these assays. The p24 assay is the most cost-
effective and easy to use surrogate assay, but does not directly
measure HIV-1 RNA and also does not reliably detect HIV-1 RNA
levels less than 10 000 copies/ml, which is essential in monitoring
response to ART. The p24 assay has been validated for subtype B, and
its performance in quantiﬁcation of antigen produced by non-B
subtypes is not well established. Although slightly more expensive
than the p24 antigen assay, the Cavidi RT assay is able to detect a
lower concentration of HIV-1 viral load (2000 copies/ml) and
theoretically should perform well on recombinant forms since it is
based on a functional protein end-product (RT).104
Finally, a new diagnostic approach may need to be validated for
monitoring ART that does not rely on the routine quantiﬁcation of
HIV-1 RNA in plasma, but uses a multiplex real-time PCR assay to
reliably detect or not detect these viruses after therapy has
suppressed virus below a clinically acceptable level. A qualitative
assay would therefore be used for monitoring until such time as
virus again becomes detectable on therapy, indicative of viral
relapse. An HIV-1 viral load assay could then be done to measure
the level of virus circulating in plasma and to perform a genotype
for antiviral resistance. This approach has been successfully used to
treat hepatitis C virus infections,105 and may be as effective and
much less expensive for monitoring therapy for HIV-1 infection
versus routinely measuring HIV viral load on all patients even
when highly active antiretroviral therapy (HAART) has effectively
suppressed virus replication in plasma below detectable levels.
7. Conclusions
Both awareness and appreciation of the limitations of any
given viral load assay is imperative when making decisions
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current commercially available HIV-1 viral load assays perform
very well in quantifying subtype B virus, these assays are not
necessarily as accurate or adequate for all non-B HIV-1 subtypes
or crossover recombinants. The targets of the currently available
assays will need to be reassessed as viral mutations as variability
continues to grow. An ideal target for a viral load assay would be
conserved or shared sequence(s) that are present in all HIV-1
subtypes, but this remains elusive. This challenge although
present in the developed world is even more important in the
developing world where the major burden of HIV and viral
diversity exists. Although there are many technical and ﬁnancial
challenges inherent to wide-scale deployment of HIV-1 viral load
assays in resource-limited areas, our goal should nevertheless be
equitable HIV care worldwide.
Genetic variation in HIV-1 subtypes or extreme divergence
within an HIV subtype may signiﬁcantly affect the ability to detect
and quantify the viral RNA in clinical specimens. Non-detection,
under-quantiﬁcation, or even over-quantiﬁcation of HIV-1 plasma
viremia, has the potential to cause serious errors in patient care.
Clinical laboratories should implement one of the newer qrtPCR
methods (i.e., m2000rt or CAP-CTM) for optimal performance of
HIV viral load testing of patients with subtype B as well as non-B
subtype infections. Our study shows that both the EQ and bDNA
assays were less reliable for accurate viral load measurements
across HIV subtypes.64 As HIV strains continue to diverge within a
given geographic area, as well as globally, it will become
increasingly important for clinical laboratories to establish and
follow the spectrum of viral genotypes causing infection in their
population, and to monitor clinical validity of their tests in
collaboration with clinical colleagues. Patients with documented
non-B subtype infections, as well as those with extreme divergence
within subtype B, may require HIV viral load testing on a different
platform if their results seem discordant with either their clinical
presentation or status. Discordant samples should be re-tested
using a second HIV-1 viral load assay that targets an alternative
gene region (i.e., gag if a pol-based assay was initially used, and vice
versa). Molecular sequencing studies should also characterize
mismatches between an assay’s probes and primers and the HIV
subtype or strain target template. Periodic evaluation of assays
may be necessary to assess their performance in detecting and
accurately quantifying divergent HIV subtypes, in order to provide
optimal performance in patients in developed and resource-poor
countries.
The expanding HIV viral diversity and the global spread of non-
B subtypes should lead to a coordinated response in both
developed and developing countries. Ensuring that all of the
genetically based critical tools used in HIV patient care (such as
viral load and resistance tests) reﬂect the viruses being seen in the
clinic and that they remain valid for clinical use is critical for
everyone. Close collaboration between clinicians and laboratory
specialists is essential to recognize challenges of ongoing viral
diversity. Establishing a laboratory network that has the capacity
to have samples with unusual characteristics tested by an
alternative assay, and in the case of discordant results send the
sample for further sequencing characterization, is an important
ﬁrst step to building the necessary infrastructure to monitor local
and global HIV-1 diversity going forward.
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